PMID: 7542045Jan 1, 1995Paper

Detection of ribonuclease H-generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides

Antisense Research and Development
R V GilesD M Tidd

Abstract

The involvement of ribonuclease H (RNase H) in antisense phenomena in intact cells has, to date, only been adequately demonstrated for microinjected Xenopus systems. The significance of RNase H for the antisense effects of oligodeoxynucleotides observed in human and other mammalian cell cultures has remained obscure, in part because of inadequate analytic methods. In this report we show that the "reverse ligation-mediated PCR" (RL-PCR) procedure permits amplification of RNA fragments produced by oligodeoxynucleotide-directed RNase H activity. We have used this procedure to demonstrate RNase H-dependent antisense effects in irreversibly permeabilized (dead) cells and reversibly permeabilized (live) cells.

References

Mar 1, 1992·The Journal of Experimental Medicine·T SkorskiB Calabretta
Apr 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·J P LeonettiB Lebleu
Jul 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·R Y Walder, J A Walder
Nov 11, 1987·Nucleic Acids Research·J F MilliganO C Uhlenbeck
Feb 11, 1994·Nucleic Acids Research·E BertrandT Grange
Apr 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·E BertrandT Grange
Jul 25, 1993·Nucleic Acids Research·R BerganL Neckers

❮ Previous
Next ❯

Citations

Feb 5, 1998·Antisense & Nucleic Acid Drug Development·W BileckiR Przewłocki
Mar 25, 1998·Antisense & Nucleic Acid Drug Development·M A MeloneA Cascino
May 21, 1998·Antisense & Nucleic Acid Drug Development·S T Crooke
Sep 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·D L SokolA M Gewirtz
Jul 26, 2002·Cancer Biotherapy & Radiopharmaceuticals·Andreas C BuckSven N Reske
Feb 13, 2004·The Journal of Biological Chemistry·Hongjiang WuStanley T Crooke
Nov 24, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·I V Lebedeva, C A Stein
Sep 17, 1998·The Journal of Biological Chemistry·G C TuY Israel
Nov 25, 2000·British Journal of Haematology·D A Fennell, F E Cotter
Jun 4, 1999·Antisense & Nucleic Acid Drug Development·R V GilesD M Tidd
Aug 18, 2000·Genes to Cells : Devoted to Molecular & Cellular Mechanisms·T KozuK Akagi
Jan 30, 2004·Annual Review of Medicine·Stanley T Crooke
Dec 25, 2007·Oligonucleotides·Zhaoyang YeRam I Mahato
Feb 24, 2001·Nucleosides, Nucleotides & Nucleic Acids·A KusunokiH Takaku
May 22, 1998·Molecular Biology of the Cell·P LorenzD L Spector
Oct 28, 2019·Bioanalysis·Christopher C StebbinsLauren F Stevenson
Apr 6, 2021·Frontiers in Bioengineering and Biotechnology·Tulsi Ram DamaseJohn P Cooke
Dec 31, 1997·Biochemical Pharmacology·C F Bennett
Oct 1, 1996·Trends in Biotechnology·S Agrawal
May 12, 2000·Biochimica Et Biophysica Acta·C F Bennett, L M Cowsert
Oct 18, 2000·Advanced Drug Delivery Reviews·S Dokka, Y Rojanasakul
May 22, 2002·Biochimica Et Biophysica Acta·Anjaneyulu MatlapudiSheldon I Feinstein
Aug 24, 1999·Pharmacology & Therapeutics·S R CooperN M Dean
Jun 16, 2004·Journal of Controlled Release : Official Journal of the Controlled Release Society·Fuxin Shi, Dick Hoekstra
Jul 20, 2007·International Journal of Radiation Oncology, Biology, Physics·Satoshi AnaiCharles J Rosser

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.